Lab validation of immune cell therapy for MCPyV-positive Merkel cell carcinoma
Validation of in Vitro Method for Anti-MCPyV Immunotherapy on Patients With Merkel Cell Carcinoma of Skin
The team will test a lab-based immune cell therapy on tumor or blood samples from adults with MCPyV-positive Merkel cell carcinoma to see how the cells respond.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 15 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Assistance Publique - Hôpitaux de Paris Academic / other |
| Locations | 1 site (Boulogne-Billancourt) |
| Trial ID | NCT06780475 on ClinicalTrials.gov |
What this trial studies
The study collects tumor or blood samples from adults with Merkel cell carcinoma who are treated or followed at Ambroise Paré Hospital and applies an anti-MCPyV cell therapy in the laboratory. Researchers will expose patient-derived samples to the proposed cell therapy in vitro and measure tumor cell killing and immune activation. The primary aim is to validate the laboratory method and identify which patient samples show a response. This is an observational, bench-based validation and does not deliver the investigational therapy to patients.
Who should consider this trial
Good fit: Ideal candidates are adults (≥18) diagnosed with Merkel cell carcinoma of the skin, especially those known or suspected to be MCPyV-positive, who are receiving local or systemic care or active follow-up at the recruiting center and can give informed consent.
Not a fit: Patients who are pregnant or breastfeeding, under guardianship, enrolled in another interventional clinical trial, or whose tumors are MCPyV-negative should expect no direct clinical benefit from participation and may be ineligible.
Why it matters
Potential benefit: If successful, this work could help develop a targeted immune cell therapy for MCPyV-positive tumors and guide selection of patients for future clinical treatment.
How similar studies have performed: Laboratory and early preclinical MCPyV-targeted immune approaches have shown promising signals, but clinical benefit in patients has not been established.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients \>= 18 years old; * Diagnosed with Merkel cell carcinoma of skin, ongoing for local treatment, systemic treatment, complementary treatment or an active follow-up; * Informed for the study and no-opposed for participation; * Affiliated with a social security scheme or in an equivalent situation. Exclusion Criteria: * Patients ongoing another interventional clinical trial; * Patients under guardianship or trusteeship; * Pregnancy or breastfeed; * Patients refusal.
Where this trial is running
Boulogne-Billancourt
- Dermato-oncology Department, Ambroise Paré Hospital, APHP — Boulogne-Billancourt, France (Recruiting)
Study contacts
- Principal investigator: Astrid Blom, MD — Dermato-oncology Department, Ambroise Paré Hospital, APHP
- Study coordinator: Astrid Blom, MD
- Email: astrid.blom@aphp.fr
- Phone: +33 (01) 49 09 44 82
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.